Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
NCT ID: NCT05387837
Last Updated: 2025-05-04
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-08-31
Study Completion Date
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
NCT05105607
Neovascular Age-related Macular Degeneration
Diabetic Macular Edema
COMPLETED
PHASE1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854
Diabetic Macular Edema
ACTIVE_NOT_RECRUITING
PHASE1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
NCT03178149
Age-Related Macular Degeneration
RECRUITING
PHASE1
Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)
NCT03216538
Neovascular Age-related Macular Degeneration
COMPLETED
PHASE1/PHASE2
A Study of ASKG712 in Patients With Diabetic Macular Edema
NCT05940428
Diabetic Macular Edema
ACTIVE_NOT_RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A Three Stage Phase 2 Study: Stage 1: Single Subcutaneous Dose Open-Label Assessment of Safety and Pharmacodynamic Response to D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor) in Subjects with Neovascular (wet) Age-Related Macular Degeneration (wAMD) or Subjects with Diabetic Macular Edema (DME). Stage 1A: Multiple Subcutaneous Dose Open-Label Assessment of Safety, Pharmacokinetics and Pharmacodynamic Response to D-4517.2 Co-administered with Aflibercept in Subjects with wAMD and DME. Stage 2: Visual Examiner-Masked, Randomized Active, Sham and Placebo Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Subcutaneously Administered D-4517.2 to Subjects with wAMD
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neovascular Age-related Macular Degeneration
Diabetic Macular Edema
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stage 1 wAMD
* Cohort A1 - 0.18 mg/kg of D-4517.2
* Cohort B1 - 0.36 mg/kg of D-4517.2
* Cohort C1 - 0.71 mg/kg of D-4517.2
* Cohort D1 - 1.5 mg/kg of D-4517.2
Group Type
EXPERIMENTAL
D-4517.2
Intervention Type
DRUG
D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Stage 1 DME
* Cohort B2 - 0.36 mg/kg of D-4517.2
* Cohort C2 - 0.71 mg/kg of D-4517.2
* Cohort D2 - 1.5 mg/kg of D-4517.2
Group Type
EXPERIMENTAL
D-4517.2
Intervention Type
DRUG
D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Stage 1A wAMD
* Cohort E1 - 2.0 mg/kg of D-4517.2 every 2 weeks
* Cohort F1 - 2.0 mg/kg of D-4517.2 every 4 weeks
Group Type
EXPERIMENTAL
D-4517.2
Intervention Type
DRUG
D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Stage 1A DME
* Cohort E2 - 2.0 mg/kg of D-4517.2 every 2 weeks
* Cohort F2 - 2.0 mg/kg of D-4517.2 every 4 weeks
Group Type
EXPERIMENTAL
D-4517.2
Intervention Type
DRUG
D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-4517.2
D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
aflibercept
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Willing and able to give informed consent, comply with all study procedures, and be likely to complete the study.
2. Demonstrated response to prior anti-VEGF treatment as defined by one or more of the following and as assessed by the Investigator for Stages 1 and 1A and confirmed by the Central Reader for Stage 2:
1. Complete resolution or partial reduction of foveal intra- and/or subretinal fluid ≥ 30% from initial diagnosis as measured by SD-OCT.
2. Increase in BCVA ≥ 2 lines from initial diagnosis using Snellen scale.
3. Female subjects may be enrolled if they are:
1. Not pregnant, lactating, or breastfeeding
2. Documented in medical records or subject self-reported to be surgically sterile or postmenopausal.
3. Female subjects of childbearing potential must practice true abstinence for at least 28 days prior to investigational product (IP) administration until 30 days after the last IP administration and have a negative serum and urine pregnancy test at Screening and Baseline Day 1, respectively, or
4. Using 2 forms of highly effective contraception, including 1 physical barrier (condom or diaphragm) plus another method, such as adequate hormonal method (eg, contraceptive implants, injectables, or oral contraceptives) or nonhormonal methods (eg, intrauterine device or spermicidals) from Screening or at least 2 weeks prior to IP administration (whichever is earlier) until 30 days after the last IP administration and having a negative serum and urine pregnancy test at Screening and Baseline Day 1, respectively.
4. Male subjects with female partners of childbearing potential may be enrolled if they are:
1. Documented to be surgically sterile (vasectomy) in medical records or subject self-reported, or
2. Agree to practice true abstinence during the study and for 30 days after the last IP administration, or
3. Agree to use 2 adequate forms of highly effective contraception during the study, 1 of which should be a physical barrier for 30 days after the last IP administration.
4. Must agree not to donate sperm during study and for 30 days following administration of the last dose of IP.
5. Subjects who complete the Aflibercept Treatment Period in Stage 1 are eligible to enroll in Stage 1A if they meet all eligibility requirements. These subjects will enter the study in the D-4517.2 Treatment Period.
6. Subjects who complete Stage 1 and/or Stage 1A are eligible to enroll in Stage 2 if they meet all eligibility requirements.
7. Ocular media clarity, pupillary dilation and individual cooperation sufficient for adequate fundus imaging in the opinion of the Investigator.
8. Recurrence of intra- or subretinal fluid at study Baseline. This inclusion criterion will be confirmed by the Sponsor or Central Reader in Stages 1 and 1A and by the Central Reader in Stage 2.
9. For subjects with bilateral disease, only one eye per subject can participate in the study. In cases where both eyes are eligible, the eye with the worse BCVA at the Screening Visit will be selected as the study eye. If both eyes have the same BCVA, the eye with the largest CST will be selected as the study eye.
Subjects With wAMD (For all Stages):
10. Male or nonpregnant female adults aged ≥50 years at time of signing the informed consent form (ICF).
11. BCVA letter score between 75 and 23 letters (ETDRS chart) (20/32 to 20/320 Snellen equivalents) inclusive in the study eye at Baseline and BCVA letter score of at least 35 letters (ETDRS chart) (20/200 Snellen equivalent) in the non-study eye.
12. Previously treated subjects with at least 3 prior IVT injections with an anti-VEGF agent (aflibercept, bevacizumab, faricimab, ranibizumab, or any other approved anti-VEGF agent) with last treatment administered between 4 and 12 weeks prior to Screening. Administration of IVT anti-VEGF agents prior to enrollment must not be more than 12 weeks apart. This inclusion criterion will be assessed by the Investigator.
13. For Stage 2, presence of a choroidal neovascular (CNV) lesion secondary to wAMD confirmed by the Central Reader.
14. The Investigator attributes the cause of the decreased vision in the study eye primarily to wAMD.
Subjects With DME (For Stages 1 and 1A only):
15. Male or nonpregnant female adults aged ≥18 years at time of signing the ICF.
16. Diagnosis of diabetes mellitus (Type 1 or Type 2). Any of the following will be considered to be sufficient evidence that diabetes is present:
1. Current regular use of oral anti-hyperglycemic agents for the treatment of diabetes.
2. Current regular use of insulin or other injectable drugs (eg, dulaglutide and liraglutide) for the treatment of diabetes.
3. Documented diabetes by American Diabetic Association (ADA) and/or World Health Organization (WHO) criteria.
17. Hemoglobin A1c (HbA1c) ≤12% at Screening.
19. BCVA letter score between 75 and 23 letters (ETDRS chart) (20/32 to 20/320 Snellen equivalents) inclusive in the study eye at Baseline.
20. Previously treated subjects with at least 5 prior IVT injections with an anti-VEGF agent (aflibercept, bevacizumab, faricimab, ranibizumab, or any other approved anti-VEGF agent) with last treatment administered between 4 and 12 weeks prior to Screening. Administration of IVT anti-VEGF agents prior to enrollment must not be more than 12 weeks apart. This inclusion criterion will be assessed by the Investigator.
21. The Investigator attributes the cause of the decreased vision in the study eye primarily to DME.
2. Demonstrated response to prior anti-VEGF treatment as defined by one or more of the following and as assessed by the Investigator for Stages 1 and 1A and confirmed by the Central Reader for Stage 2:
1. Complete resolution or partial reduction of foveal intra- and/or subretinal fluid ≥ 30% from initial diagnosis as measured by SD-OCT.
2. Increase in BCVA ≥ 2 lines from initial diagnosis using Snellen scale.
3. Female subjects may be enrolled if they are:
1. Not pregnant, lactating, or breastfeeding
2. Documented in medical records or subject self-reported to be surgically sterile or postmenopausal.
3. Female subjects of childbearing potential must practice true abstinence for at least 28 days prior to investigational product (IP) administration until 30 days after the last IP administration and have a negative serum and urine pregnancy test at Screening and Baseline Day 1, respectively, or
4. Using 2 forms of highly effective contraception, including 1 physical barrier (condom or diaphragm) plus another method, such as adequate hormonal method (eg, contraceptive implants, injectables, or oral contraceptives) or nonhormonal methods (eg, intrauterine device or spermicidals) from Screening or at least 2 weeks prior to IP administration (whichever is earlier) until 30 days after the last IP administration and having a negative serum and urine pregnancy test at Screening and Baseline Day 1, respectively.
4. Male subjects with female partners of childbearing potential may be enrolled if they are:
1. Documented to be surgically sterile (vasectomy) in medical records or subject self-reported, or
2. Agree to practice true abstinence during the study and for 30 days after the last IP administration, or
3. Agree to use 2 adequate forms of highly effective contraception during the study, 1 of which should be a physical barrier for 30 days after the last IP administration.
4. Must agree not to donate sperm during study and for 30 days following administration of the last dose of IP.
5. Subjects who complete the Aflibercept Treatment Period in Stage 1 are eligible to enroll in Stage 1A if they meet all eligibility requirements. These subjects will enter the study in the D-4517.2 Treatment Period.
6. Subjects who complete Stage 1 and/or Stage 1A are eligible to enroll in Stage 2 if they meet all eligibility requirements.
7. Ocular media clarity, pupillary dilation and individual cooperation sufficient for adequate fundus imaging in the opinion of the Investigator.
8. Recurrence of intra- or subretinal fluid at study Baseline. This inclusion criterion will be confirmed by the Sponsor or Central Reader in Stages 1 and 1A and by the Central Reader in Stage 2.
9. For subjects with bilateral disease, only one eye per subject can participate in the study. In cases where both eyes are eligible, the eye with the worse BCVA at the Screening Visit will be selected as the study eye. If both eyes have the same BCVA, the eye with the largest CST will be selected as the study eye.
Subjects With wAMD (For all Stages):
10. Male or nonpregnant female adults aged ≥50 years at time of signing the informed consent form (ICF).
11. BCVA letter score between 75 and 23 letters (ETDRS chart) (20/32 to 20/320 Snellen equivalents) inclusive in the study eye at Baseline and BCVA letter score of at least 35 letters (ETDRS chart) (20/200 Snellen equivalent) in the non-study eye.
12. Previously treated subjects with at least 3 prior IVT injections with an anti-VEGF agent (aflibercept, bevacizumab, faricimab, ranibizumab, or any other approved anti-VEGF agent) with last treatment administered between 4 and 12 weeks prior to Screening. Administration of IVT anti-VEGF agents prior to enrollment must not be more than 12 weeks apart. This inclusion criterion will be assessed by the Investigator.
13. For Stage 2, presence of a choroidal neovascular (CNV) lesion secondary to wAMD confirmed by the Central Reader.
14. The Investigator attributes the cause of the decreased vision in the study eye primarily to wAMD.
Subjects With DME (For Stages 1 and 1A only):
15. Male or nonpregnant female adults aged ≥18 years at time of signing the ICF.
16. Diagnosis of diabetes mellitus (Type 1 or Type 2). Any of the following will be considered to be sufficient evidence that diabetes is present:
1. Current regular use of oral anti-hyperglycemic agents for the treatment of diabetes.
2. Current regular use of insulin or other injectable drugs (eg, dulaglutide and liraglutide) for the treatment of diabetes.
3. Documented diabetes by American Diabetic Association (ADA) and/or World Health Organization (WHO) criteria.
17. Hemoglobin A1c (HbA1c) ≤12% at Screening.
19. BCVA letter score between 75 and 23 letters (ETDRS chart) (20/32 to 20/320 Snellen equivalents) inclusive in the study eye at Baseline.
20. Previously treated subjects with at least 5 prior IVT injections with an anti-VEGF agent (aflibercept, bevacizumab, faricimab, ranibizumab, or any other approved anti-VEGF agent) with last treatment administered between 4 and 12 weeks prior to Screening. Administration of IVT anti-VEGF agents prior to enrollment must not be more than 12 weeks apart. This inclusion criterion will be assessed by the Investigator.
21. The Investigator attributes the cause of the decreased vision in the study eye primarily to DME.
Exclusion Criteria
Medical Conditions:
1. History, within 6 months prior to Screening, of any of the following: myocardial infarction, any cardiac event requiring hospitalization, treatment for acute congestive heart failure, transient ischemic attack or stroke.
2. Uncontrolled hypertension with systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg (while subject at rest) at the Screening Visit. If the subject's initial reading exceeds these values, a second reading may be taken 30 minutes later on the same day. If the subject's BP is controlled by antihypertensive medication, the subject should be taking the same medication continuously for at least 30 days prior to Day 1.
3. Currently untreated diabetes mellitus, uncontrolled diabetes mellitus defined as HbA1c \> 12%, or previously untreated subjects with diabetes mellitus who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1.
4. Chronic renal disease requiring chronic hemodialysis or renal transplantation.
5. Abnormal liver function, as defined by transaminase or total bilirubin 2 times above the upper limit of normal at the Screening Visit.
6. Medical history of Wolff-Parkinson-White Syndrome, family history of long QT or planned initiation or currently on medication prolonging QT time during the trial.
7. Known allergy to constituents of the study drug formulation, aflibercept, or clinically relevant hypersensitivity to fluorescein used by the subject during the study.
8. Serious systemic infections:
1. Any active infections for which systemic anti-infectives were used within 4 weeks before Screening Visit.
2. Recurrent or chronic infections or other active infections that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.
9. Any organic or psychiatric disorder, or laboratory abnormality which, in the opinion of the Investigator, will prevent the subject from completing the study activities as in the protocol or interfere with the interpretation of the study results.
10. An underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal) or history of other disease, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of study drug, might affect interpretation of the results of the study or which, in the opinion of the Investigator, renders the subject at unacceptable risk of treatment complications by participating in the trial.
11. Any major illness or surgical procedure within 1 month before Screening.
12. History of other diseases, physical examination finding, historical or current clinical laboratory finding giving reasonable suspicion of condition that contraindicates the use of the IP or that might affect the interpretation of the results of the study or renders the subject at high risk for treatment complications, in the opinion of the Investigator.
13. Positive screen antibodies for hepatitis B or hepatitis C virus subsequently confirmed to suggest active infection, or HIV type 1 or 2 antibodies.
Prior/Concomitant Therapy:
14. Participation in any investigational study within 30 days prior to Screening, or planned use of an IP or device during the study; any exposure to a prior investigational drug product must be fully washed out (at least 5 half-lives).
15. Chronic alcohol or drug abuse or any condition that, in the Investigator's opinion, makes them an unreliable study participant or unlikely to complete the trial.
16. Use of systemic medications known to be toxic to the lens, retina or optic nerve (eg, deferoxamine, chloroquine/hydroxy-chloroquine, tamoxifen, phenothiazines, and ethambutol) used during the 6 month or 5 half-lives (whichever is longer) prior to Day 1 or likely need to be used.
17. Use of systemic immunomodulatory treatments (eg, interleukin-6 inhibitors) within 6 months or 5 half-lives (whichever is longer) prior to Day 1.
18. Use of systemic corticosteroids (ie, oral, IM, IV, intranasal) within 1 month prior to Day 1 and no corticosteroids anticipated throughout the trial.
19. Systemic treatment for suspected or active systemic infections.
20. Administration of systemic anti-VEGF or pro-VEGF treatment within 180 days or 5 half-lives, whichever is longer, before Screening Visit.
21. Received blood transfusion within 3 months prior to the Screening Visit.
22. High risk proliferative diabetic retinopathy (DR) as assessed by the Investigator.
23. Any history of or ongoing rubeosis iridis.
24. Prior macular photocoagulation (defined as ≥ 100 burns placed previously outside of the posterior pole) in the study eye prior to Screening or expected to be received between the Screening Visit and Day 1.
25. History of treatment with periocular or IVT corticosteroids in the study eye in the past 3 months and no such treatment planned for the time between Screening and Day 1.
26. Treatment of DME or DR with macular laser.
27. Any intraocular surgery (eg, Cataract surgery) performed within 3 months prior to Screening or planned during the trial in the study eye.
28. Spherical equivalent of the refractive error in the study eye demonstrating more than -8 diopters of myopia (prior to cataract or refractive surgery) at the Screening Visit.
29. Uncontrolled intraocular pressure (IOP), defined as an IOP ≥ 25 mmHg, despite antiglaucoma medications in the study eye(s) at the time of Screening or controlled glaucoma that requires management with \>2 topical hypotensive medications.
30. Presence of any clinically significant epiretinal membrane or vitreomacular traction in the study eye(s).
31. History or evidence of any of the following surgeries or procedures in the study eye(s):
1. Sub-macular surgery or other surgical intervention.
2. Prior retinal detachment or macular hole interventions.
3. History of vitreoretinal surgery or vitrectomy.
4. Photodynamic therapy or thermal laser retinal treatment of the macula or fovea.
5. Intraocular laser treatments for glaucoma (eg, selective laser trabeculoplasty or peripheral iridotomy).
6. Glaucoma filtering surgery (eg, trabeculectomy) or glaucoma drainage device (eg, Ahmed valve or Baerveldt valve) including minimally invasive glaucoma shunts (eg, minimally invasive glaucoma surgery.
7. Neodymium: yttrium-aluminum-garnet (Nd:YAG) laser capsulotomy within the 30 days prior to the Screening Visit.
8. Corneal refractive procedures (laser-assisted in situ keratomileusis \[LASIK\] or photorefractive keratectomy) within the 6 months prior to the Screening Visit or planned during the study.
9. Corneal transplantation surgery.
32. History or clinical evidence of other concurrent conditions deemed by the Investigator likely to impact the subject's clinical safety or interfere with interpretation of study results including, but not limited to:
1. Inflammatory conditions of the anterior or posterior segment (eg, chronic keratoconjunctivitis, uveitis, retinal vasculitis, neuritis, iritis, scleritis, or blepharitis) in either eye.
2. Subretinal hemorrhage that is ≥ 50% of the total CNV lesion area.
3. Any vitreous opacity that prevents proper visualization of the fundus and/or adversely alters visual acuity, in the opinion of the Investigator.
4. Prior radiation therapy in the region of the eyes.
33. Presence of fibrosis as measured by SD-OCT and assessed by the Central Reader in Stages 1 and 1A. Fibrosis or atrophy of more than 50% of the lesion size and/or involving the foveal center of the study eye at Screening; these criteria will be assessed by the Central Reader in Stage 2.
34. Current or history of vitreous hemorrhage in the study eye within 3 months of Screening.
35. Any history of active or suspected ocular or periocular bacterial, viral, fungal or parasitic infections (eg, infectious or noninfectious conjunctivitis, keratitis, scleritis, endophthalmitis or other) in either eye within 30 days prior to Screening Visit.
Other:
36. Has any finding that, in the view of the Investigator or Medical Monitor, would compromise the subject's safety requirements.
37. Any previous treatment with ILUVIEN, Ozurdex, or Retisert (fluocinolone acetonide IVT implant) in the non-study eye.
38. DME subjects who have BCVA of hand motion or worse in the non-study eye or non-physical presence of a non-study eye (ie, monocular).
1. History, within 6 months prior to Screening, of any of the following: myocardial infarction, any cardiac event requiring hospitalization, treatment for acute congestive heart failure, transient ischemic attack or stroke.
2. Uncontrolled hypertension with systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg (while subject at rest) at the Screening Visit. If the subject's initial reading exceeds these values, a second reading may be taken 30 minutes later on the same day. If the subject's BP is controlled by antihypertensive medication, the subject should be taking the same medication continuously for at least 30 days prior to Day 1.
3. Currently untreated diabetes mellitus, uncontrolled diabetes mellitus defined as HbA1c \> 12%, or previously untreated subjects with diabetes mellitus who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1.
4. Chronic renal disease requiring chronic hemodialysis or renal transplantation.
5. Abnormal liver function, as defined by transaminase or total bilirubin 2 times above the upper limit of normal at the Screening Visit.
6. Medical history of Wolff-Parkinson-White Syndrome, family history of long QT or planned initiation or currently on medication prolonging QT time during the trial.
7. Known allergy to constituents of the study drug formulation, aflibercept, or clinically relevant hypersensitivity to fluorescein used by the subject during the study.
8. Serious systemic infections:
1. Any active infections for which systemic anti-infectives were used within 4 weeks before Screening Visit.
2. Recurrent or chronic infections or other active infections that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.
9. Any organic or psychiatric disorder, or laboratory abnormality which, in the opinion of the Investigator, will prevent the subject from completing the study activities as in the protocol or interfere with the interpretation of the study results.
10. An underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal) or history of other disease, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of study drug, might affect interpretation of the results of the study or which, in the opinion of the Investigator, renders the subject at unacceptable risk of treatment complications by participating in the trial.
11. Any major illness or surgical procedure within 1 month before Screening.
12. History of other diseases, physical examination finding, historical or current clinical laboratory finding giving reasonable suspicion of condition that contraindicates the use of the IP or that might affect the interpretation of the results of the study or renders the subject at high risk for treatment complications, in the opinion of the Investigator.
13. Positive screen antibodies for hepatitis B or hepatitis C virus subsequently confirmed to suggest active infection, or HIV type 1 or 2 antibodies.
Prior/Concomitant Therapy:
14. Participation in any investigational study within 30 days prior to Screening, or planned use of an IP or device during the study; any exposure to a prior investigational drug product must be fully washed out (at least 5 half-lives).
15. Chronic alcohol or drug abuse or any condition that, in the Investigator's opinion, makes them an unreliable study participant or unlikely to complete the trial.
16. Use of systemic medications known to be toxic to the lens, retina or optic nerve (eg, deferoxamine, chloroquine/hydroxy-chloroquine, tamoxifen, phenothiazines, and ethambutol) used during the 6 month or 5 half-lives (whichever is longer) prior to Day 1 or likely need to be used.
17. Use of systemic immunomodulatory treatments (eg, interleukin-6 inhibitors) within 6 months or 5 half-lives (whichever is longer) prior to Day 1.
18. Use of systemic corticosteroids (ie, oral, IM, IV, intranasal) within 1 month prior to Day 1 and no corticosteroids anticipated throughout the trial.
19. Systemic treatment for suspected or active systemic infections.
20. Administration of systemic anti-VEGF or pro-VEGF treatment within 180 days or 5 half-lives, whichever is longer, before Screening Visit.
21. Received blood transfusion within 3 months prior to the Screening Visit.
22. High risk proliferative diabetic retinopathy (DR) as assessed by the Investigator.
23. Any history of or ongoing rubeosis iridis.
24. Prior macular photocoagulation (defined as ≥ 100 burns placed previously outside of the posterior pole) in the study eye prior to Screening or expected to be received between the Screening Visit and Day 1.
25. History of treatment with periocular or IVT corticosteroids in the study eye in the past 3 months and no such treatment planned for the time between Screening and Day 1.
26. Treatment of DME or DR with macular laser.
27. Any intraocular surgery (eg, Cataract surgery) performed within 3 months prior to Screening or planned during the trial in the study eye.
28. Spherical equivalent of the refractive error in the study eye demonstrating more than -8 diopters of myopia (prior to cataract or refractive surgery) at the Screening Visit.
29. Uncontrolled intraocular pressure (IOP), defined as an IOP ≥ 25 mmHg, despite antiglaucoma medications in the study eye(s) at the time of Screening or controlled glaucoma that requires management with \>2 topical hypotensive medications.
30. Presence of any clinically significant epiretinal membrane or vitreomacular traction in the study eye(s).
31. History or evidence of any of the following surgeries or procedures in the study eye(s):
1. Sub-macular surgery or other surgical intervention.
2. Prior retinal detachment or macular hole interventions.
3. History of vitreoretinal surgery or vitrectomy.
4. Photodynamic therapy or thermal laser retinal treatment of the macula or fovea.
5. Intraocular laser treatments for glaucoma (eg, selective laser trabeculoplasty or peripheral iridotomy).
6. Glaucoma filtering surgery (eg, trabeculectomy) or glaucoma drainage device (eg, Ahmed valve or Baerveldt valve) including minimally invasive glaucoma shunts (eg, minimally invasive glaucoma surgery.
7. Neodymium: yttrium-aluminum-garnet (Nd:YAG) laser capsulotomy within the 30 days prior to the Screening Visit.
8. Corneal refractive procedures (laser-assisted in situ keratomileusis \[LASIK\] or photorefractive keratectomy) within the 6 months prior to the Screening Visit or planned during the study.
9. Corneal transplantation surgery.
32. History or clinical evidence of other concurrent conditions deemed by the Investigator likely to impact the subject's clinical safety or interfere with interpretation of study results including, but not limited to:
1. Inflammatory conditions of the anterior or posterior segment (eg, chronic keratoconjunctivitis, uveitis, retinal vasculitis, neuritis, iritis, scleritis, or blepharitis) in either eye.
2. Subretinal hemorrhage that is ≥ 50% of the total CNV lesion area.
3. Any vitreous opacity that prevents proper visualization of the fundus and/or adversely alters visual acuity, in the opinion of the Investigator.
4. Prior radiation therapy in the region of the eyes.
33. Presence of fibrosis as measured by SD-OCT and assessed by the Central Reader in Stages 1 and 1A. Fibrosis or atrophy of more than 50% of the lesion size and/or involving the foveal center of the study eye at Screening; these criteria will be assessed by the Central Reader in Stage 2.
34. Current or history of vitreous hemorrhage in the study eye within 3 months of Screening.
35. Any history of active or suspected ocular or periocular bacterial, viral, fungal or parasitic infections (eg, infectious or noninfectious conjunctivitis, keratitis, scleritis, endophthalmitis or other) in either eye within 30 days prior to Screening Visit.
Other:
36. Has any finding that, in the view of the Investigator or Medical Monitor, would compromise the subject's safety requirements.
37. Any previous treatment with ILUVIEN, Ozurdex, or Retisert (fluocinolone acetonide IVT implant) in the non-study eye.
38. DME subjects who have BCVA of hand motion or worse in the non-study eye or non-physical presence of a non-study eye (ie, monocular).
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ashvattha Therapeutics, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Macro Trials
Los Angeles, California, United States
Site Status
University Retina - Lemont
Lemont, Illinois, United States
Site Status
Midwest Eye Institute - North
Indianapolis, Indiana, United States
Site Status
Cumberland Valley Retina Consultants
Hagerstown, Maryland, United States
Site Status
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Site Status
Springield Clinic
Springfield, Missouri, United States
Site Status
The Retina Institute - Clayton Office
St Louis, Missouri, United States
Site Status
Envision Ocular, LLC
Bloomfield, New Jersey, United States
Site Status
Erie Retina Research
Eire, Pennsylvania, United States
Site Status
Texas Retina Associates - Arlington
Arlington, Texas, United States
Site Status
Austin Retina Associates
Austin, Texas, United States
Site Status
Medical Center Ophthalmology Associates - Northwest
San Antonio, Texas, United States
Site Status
Retinal Consultants of San Antonio
San Antonio, Texas, United States
Site Status
Strategic Clinical Research Group
Willow Park, Texas, United States
Site Status
Virginia Retina Center
Leesburg, Virginia, United States
Site Status
West Virginia University Eye Institute
Morgantown, West Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D-4517-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05859776
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
NCT04594681
TERMINATED
PHASE1
Evaluation of IBI302 Injection in nAMD or DME
NCT05961007
SUSPENDED
PHASE1/PHASE2
A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
NCT04597918
COMPLETED
PHASE2
Safety and Efficacy of AM712 in Patients with NAMD
NCT05345769
COMPLETED
PHASE1
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
NCT03790852
TERMINATED
PHASE1
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
NCT05698329
ACTIVE_NOT_RECRUITING
PHASE1
Phase 1 Study of CM082 in Patients With wAMD
NCT02452385
SUSPENDED
PHASE1
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
NCT03869684
TERMINATED
PHASE2
Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration
NCT05953012
COMPLETED
PHASE1
Safety and Tolerability of Oral CM082 in Patients With wAMD
NCT03710863
UNKNOWN
PHASE2
Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736
COMPLETED
PHASE2/PHASE3
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
NCT00138632
COMPLETED
PHASE1/PHASE2
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153
RECRUITING
PHASE1/PHASE2
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
NCT04895293
COMPLETED
PHASE1/PHASE2
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT03295877
COMPLETED
PHASE1
A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration
NCT05456828
ACTIVE_NOT_RECRUITING
PHASE1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT06850922
RECRUITING
PHASE1/PHASE2
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
NCT00511706
COMPLETED
PHASE2
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
NCT05919693
COMPLETED
PHASE1/PHASE2
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
NCT04085341
COMPLETED
PHASE2
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
NCT03249740
COMPLETED
PHASE1
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
NCT00321997
COMPLETED
PHASE2/PHASE3